Company / SG&A Expense
CRISPR Therapeutics AG SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$73.5M
FY2025
5-year range
$73.0M / $102.5M
FY2021-FY2025
Trend
+0.8%
vs FY2024
Sector context
#128 of 211
Health Care
What the data says
At $74M, CRISPR Therapeutics AG's sg&a expense ranks #84 of 211 in the Health Care sector. SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $74M.
Based on SEC 10-K filings.
$74M in FY2025 with a 5-year CAGR of -3.0%.
Improved from $76M to $74M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -10.5%
- 5-Year CAGR
- -3.0%
- 10-Year CAGR
- -
Sector benchmark
#84 of 211 in Health CareTop 39% of 211This company $73.5M Sector average $728.7M
▼
-89.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -3.0%, indicating a declining trend.
- In FY2025, sg&a expense increased 0.8% year-over-year.
- Ranks #128 out of 211 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.5M | +0.8% |
| FY2024 | $73.0M | -4.2% |
| FY2023 | $76.2M | -25.7% |
| FY2022 | $102.5M | +2.8% |
| FY2021 | $99.7M | +16.3% |
| FY2020 | $85.7M | +35.1% |
| FY2019 | $63.5M | +31.5% |
| FY2018 | $48.3M | +34.7% |
| FY2017 | $35.8M | +15.4% |
| FY2016 | $31.1M | +131.7% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026